Pageviews:
Introduction
Obesity is one of the most expensive medical conditions in the world. It increases the risk of type 2 diabetes, heart disease, stroke, certain cancers, and a range of joint problems, all of which require ongoing treatment and generate enormous healthcare costs. In the United States, the annual medical costs directly attributable to obesity are estimated to run into hundreds of billions of dollars. So when a new class of drugs appeared to cause significant and sustained weight loss, the pharmaceutical companies that make them and many public health researchers began to argue that these medications could do something extraordinary: not just help individuals, but reduce the overall cost of healthcare for entire populations. The drugs in question are GLP-1 agonists, sold under brand names including Ozempic, Wegovy, and Mounjaro, produced by the Danish pharmaceutical company Novo Nordisk and the American company Eli Lilly. A recent study has tested that claim, and the results are more complicated than the original story suggested.
What GLP-1 Drugs Do
GLP-1 is a hormone that the human body naturally produces after eating. Its main roles are to trigger the release of insulin, slow the emptying of the stomach, and send signals to the brain indicating that the body has had enough food. GLP-1 agonist drugs mimic this hormone, amplifying its effects. In clinical trials, patients on these drugs have lost fifteen to twenty percent of their body weight, a result that was difficult or impossible to achieve with previous medications. The drugs have also shown benefits beyond weight loss, including reductions in the risk of heart attacks and improvements in blood sugar control. Novo Nordisk and Eli Lilly argue that by helping people achieve and maintain lower body weight, the drugs will reduce the incidence of obesity-related conditions and therefore reduce the cost of treating those conditions over time. The logic is straightforward and plausible. An insurance company that pays to treat ten patients for diabetes, heart disease, and joint replacements would prefer to prevent those conditions for a fraction of the cost.
The Unexpected Finding
The study that tested this argument produced a counterintuitive result. Researchers looked at the actual healthcare spending of obese patients before and after they began taking GLP-1 drugs. Before starting the medication, the average annual medical cost per patient was approximately twelve thousand seven hundred dollars. Two years after starting the medication, the average annual cost for the same group had risen to approximately eighteen thousand five hundred dollars, an increase of forty-six percent. In comparison, obese patients who did not take the drugs saw their medical costs rise by only fourteen percent over the same period. What is especially concerning is that the increase in spending did not come with a corresponding reduction in the conditions these drugs are supposed to prevent. Patients on GLP-1 drugs were still requiring medication for high blood pressure and high cholesterol. The rates of heart attacks, strokes, and type 2 diabetes did not fall appreciably. The drugs appeared to be driving weight loss without, in the short to medium term, translating that weight loss into reduced medical spending.
Why the Numbers Look This Way
Several explanations have been proposed for this finding. First, the drugs themselves are extremely expensive. In the United States, Ozempic costs over one thousand dollars per month for patients without insurance coverage. Even for insured patients, the drug cost adds significantly to overall medical spending. Second, losing substantial weight often triggers or reveals other medical issues that require attention, from loose skin requiring surgical intervention to nutritional deficiencies requiring supplementation. Third, the benefits of reduced obesity on long-term conditions like heart disease may simply take longer than two years to show up in the data. A person who avoids a heart attack at age sixty because they lost significant weight at age fifty may not appear in a study that only tracks two years of outcomes. The researchers who produced the study are careful to note that these drugs may still prove their value over a longer time horizon, but they caution against the assumption that the healthcare savings will materialise automatically or quickly.
What This Means for India
India has a complex relationship with these drugs. On one hand, India faces a growing burden of obesity and type 2 diabetes, driven by changing diets, urbanisation, and increasingly sedentary lifestyles. On the other hand, the drugs cost several thousand rupees per dose, placing them well beyond the reach of most Indian patients. Eli Lilly recently launched Mounjaro in India at a price of approximately four thousand rupees per weekly injection, meaning a patient would need to spend roughly two lakh rupees annually to stay on the drug. Indian pharmaceutical companies are preparing to produce generic versions of these drugs, which could reduce the cost dramatically, but they face technical challenges because GLP-1 drugs are biologics, meaning they are complex proteins grown in living cells that cannot be copied exactly the way a simple chemical molecule can be.
Final Thoughts
The weight-loss drug story illustrates a broader challenge in healthcare economics: the gap between what a treatment does in a clinical trial and what it achieves at the level of an entire healthcare system is often larger than initial projections suggest. Drugs that are effective for individuals may not reduce systemic costs, at least not in the time frames that policy-makers and insurance companies need to plan around. This does not mean GLP-1 drugs are not valuable. For the individual patients who use them effectively, the benefits are real and significant. But it does mean that the claim that these drugs will pay for themselves by reducing obesity-related medical costs deserves more scrutiny than the pharmaceutical industry’s promotional materials typically provide.